Document:

<PAGE>

                                                                   Exhibit 10.10
                                                                   -------------

                                PLEDGE AGREEMENT

     PLEDGE AGREEMENT dated as of December 27, 2000 from Curis, Inc., a Delaware
corporation (the "Pledgor"), to Fleet National Bank (the "Pledgee").

     1.  PLEDGE.  The Pledgor hereby pledges and assigns to the Pledgee, and
hereby grants a security interest to the Pledgee in, 100 shares of Common Stock,
$0.001 par value, of Curis Securities Corporation, a Massachusetts corporation
(the "Company"), such shares (together with any and all other rights and
property now or hereafter pledged hereunder) being herein called the
"Collateral".  The Pledgor is simultaneously herewith delivering to the Pledgee
the certificate or certificates representing the Collateral, together with a
duly executed blank stock power transferring same.

     2.  SECURITY.  This Agreement is made with the Pledgee to secure the
following (collectively, the "Obligations"): (i) the obligations of the Pledgor
hereunder and/or under that certain letter agreement of even date herewith (the
"Loan Agreement") between the Pledgor and the Pledgee, (ii) the $5,000,000 face
principal amount promissory note of the Pledgor (the "Term Note") described in
the Loan Agreement, and (iii) all other obligations, agreements, covenants,
undertakings and liabilities of the Company and/or the Pledgor to the Pledgee,
all whether now existing or hereafter arising.

     3.  REPRESENTATIONS AND WARRANTIES.  The Pledgor represents, warrants and
agrees that: (a) the Collateral is validly issued, fully paid and non-
assessable, and the Pledgor has good and valid title to the same, free and clear
of any liens, charges or encumbrances thereon or affecting the title thereto
(except for the security interest created hereby); (b) the Pledgor has good
right and lawful authority to pledge, assign, transfer, deliver, deposit, set
over and confirm unto the Pledgee the Collateral as provided herein and will
warrant and defend the title thereto and the lien thereon conveyed to the
Pledgee by this Agreement against all claims of all Persons (as defined in the
Loan Agreement) and will maintain and preserve such lien; (c) the execution,
delivery and performance of this Agreement and the delivery of the Collateral to
the Pledgee do not and will not contravene the charter documents or by-laws of
the Company or the Pledgor or any agreement, commitment, indenture, contract or
other obligation or restriction affecting the Company or the Pledgor or any of
their respective properties; (d) this Agreement and the delivery of the
Collateral to the Pledgee create in the Pledgee a fully perfected first security
interest in the Collateral; (e) the Pledgor owns and will at all times own 100%
of the outstanding equity securities of the Company and the Collateral from time
to time pledged to the Pledgee by the Pledgor constitutes and will continue to
constitute 100% of each class of outstanding equity securities of the Company;
and (f) this Agreement is the legal, valid and binding obligation of the Pledgor
enforceable in accordance with its terms.  The Pledgor covenants that Pledgor
will have the like title to and right to pledge any other property of the
Pledgor at any time hereafter required to be pledged to the Pledgee hereunder,
that the Pledgee will have a like security interest in such other property and
that Pledgor will likewise defend the Pledgee's rights and security interest
therein.

<PAGE>

     4.  EVENTS OF DEFAULT.  As used herein, an Event of Default shall be deemed
to have occurred upon the occurrence of any one or more of the following: (a)
any representation or warranty of the Pledgor and/or the Company made herein or
made in connection with the execution and delivery of the Loan Agreement or in
connection with any of the transactions contemplated thereby (including, without
limitation, any representation made by the Company in its inducement letter of
even date herewith) shall at any time prove to have been incorrect in any
material respect when made; or (b) the Pledgor and/or the Company shall fail to
perform, fulfill or observe any covenant or agreement contained herein and such
failure shall continue unremedied for thirty (30) days after written notice
thereof to the Pledgor; or (c) any default shall exist, beyond the expiration of
any applicable notice and/or grace period, under any Obligation; or (d) any
"Event of Default" (as defined in the Loan Agreement) shall exist and shall
continue uncured beyond the expiration of any applicable notice and/or grace
period; or (e) there shall be filed by or against the Pledgor and/or the Company
any voluntary or involuntary case or proceeding seeking discharge, arrangement,
reorganization or other relief under any bankruptcy, insolvency or similar law
now or hereafter in effect (other than an involuntary proceeding filed without
the consent or acquiescence of the Pledgor or the Company and dismissed within
60 days of the commencement thereof), or the Pledgor and/or the Company shall
make a general assignment for the benefit of creditors or a trustee or receiver
or similar official shall be appointed for the Pledgor and/or the Company or any
of the Pledgor's and/or the Company's property; or (e) the Collateral pledged
hereunder in which the Pledgee has a fully perfected first priority security
interest shall for any reason not constitute 100% of the outstanding capital
stock of the Company.  Unless and until an Event of Default shall have occurred
and be continuing, the Pledgor shall be entitled to vote any and all shares of
the Collateral and give consents, waivers and ratifications in respect thereof;
PROVIDED, HOWEVER, that no vote shall be cast or consent, waiver or ratification
given or action taken which would violate any of the provisions hereof or of the
Loan Agreement or any instrument or agreement executed by the Pledgor and/or the
Company and delivered pursuant to or in connection with the Loan Agreement or
which would involve any violation of any of such provisions.  All such rights to
vote and give consents, waivers and ratifications shall cease in case an Event
of Default shall occur and be continuing and the Pledgee shall give the notice
referred to in the following sentence.  At any time after the occurrence and
during the continuance of an Event of Default, and upon written notice by the
Pledgee of its intention to do so, the Pledgee may vote any or all shares of the
Collateral (whether or not transferred as hereinafter provided) and give all
consents, waivers and ratifications in respect thereof and otherwise act with
respect thereto as though it were the outright owner thereof (the Pledgor hereby
irrevocably constituting and appointing the Pledgee the proxy and attorney-in-
fact of the Pledgor, with full power of substitution, so to do), and at any time
the Pledgee may transfer into the Pledgee's name, or into the name of the
Pledgee's nominee, any or all shares of the Collateral.  The Pledgor hereby
irrevocably constitutes and appoints the Pledgee as the Pledgor's agent and
attorney-in-fact, with full power of substitution, upon the occurrence and
during the continuance of any Event of Default, to execute (in the name and on
behalf of the Pledgor) and deliver all such stock transfer powers and other
documents which the Pledgee may reasonably require in order to carry out the
intent of this Section 4.  The Pledgee being a secured party with respect to the
Collateral, the rights and powers conferred by this Section are expressly agreed
to be coupled with an interest and, therefore, irrevocable.

                                      -2-
<PAGE>

     5.  DIVIDENDS.  Unless and until an Event of Default shall have occurred
and be continuing and written notice of such Event of Default shall have been
given to the Pledgor and the Company, all cash dividends paid in respect of the
Collateral may be received by the Pledgor; otherwise all dividends shall be paid
to the Pledgee.  Nothing contained herein, however, will be deemed to authorize
the payment to the Pledgor of any dividends other than those, if any, which are
expressly permitted under the Loan Agreement.

     6.  REMEDIES IN CASE OF AN EVENT OF DEFAULT.  In case an Event of Default
shall have occurred and be continuing, the Pledgee shall have the right to
exercise in respect of the Collateral all the rights and remedies available to a
secured party under the Uniform Commercial Code in effect at the time in The
Commonwealth of Massachusetts and may also exercise all other rights and
remedies permitted under the laws of The Commonwealth of Massachusetts or any
other applicable jurisdiction.  After the occurrence and during the continuance
of an Event of Default, the Pledgee may, upon ten (10) days' notice in writing
to the Pledgor (the Pledgor agreeing that such notice shall be deemed to meet
any requirement for reasonable notice), sell, assign and deliver the whole or,
from time to time, any part of the Collateral, or any interest in any part
thereof, at any private sale or at public auction, with or without demand,
advertisement or notice of the time or place of sale or adjournment thereof or
otherwise, for cash or for other property, for immediate or future delivery, and
for such price or prices and on such terms as the Pledgee in its uncontrolled
discretion may determine, the Pledgor hereby waiving and releasing any and all
right or equity of redemption whether before or after sale hereunder; at any
such sale the Pledgee may bid for and purchase the whole or any portion of the
Collateral and may make payment therefor by any means.  The Pledgee shall apply
the cash proceeds actually received by it from any sale or other disposition,
together with any other moneys at the time held by it hereunder, to the
reasonable expenses of retaking, holding, preparing for sale, selling and the
like, to reasonable attorneys' fees, and all reasonable legal expenses, travel
and other expenses which may be incurred by the Pledgee in collecting or
attempting to collect any of the Obligations or to enforce this Agreement or in
the prosecution or defense of any action or proceeding related to the subject
matter of this Agreement; and then to such sums in such order as to principal or
interest remaining unpaid as the Pledgee in its sole discretion may reasonably
determine, and any surplus shall be paid to the Pledgor and the Pledgor shall
remain liable for any deficiency.  The Pledgee shall not be required to resort
to or marshall any present or future security for, or guaranties of, the
obligations secured hereby (including, but not limited to, this Agreement and
the Collateral pledged hereunder), or to resort to any such security or
guaranties in any particular order.  In realizing on the Collateral, the Pledgee
shall not be required to give notice to, or join in any action, or otherwise
proceed in any way against the Company or any other property now or hereafter
pledged to the Pledgee by the Company, the Pledgor or any other Person.  The
Pledgee's remedies shall be cumulative with all other rights, however existing
or arising, and may be exercised concurrently or separately.  Neither failure
nor delay on the Pledgee's part to exercise any right, remedy, power or
privilege provided for herein or by statute or at law or in equity shall operate
as a waiver thereof, nor shall any single or partial exercise of any such right,
remedy, power or privilege preclude any other further exercise thereof or the
exercise of any other right, remedy, power or privilege.

                                      -3-
<PAGE>

     The Pledgor recognizes that the Pledgee may be unable to effect a public
sale of the Collateral by reason of certain prohibitions contained in the
Securities Act of 1933, as amended (the "Act"), but may be compelled to resort
to one or more private sales thereof to a restricted group of purchasers who
will be obligated to agree, among other things, to acquire such securities for
their own account, for investment and not with a view to the distribution or
resale thereof.  The Pledgor agrees that any such private sales may be at prices
and on other terms less favorable to the seller than if sold at public sales and
that such private sales shall not be deemed to have been made in a commercially
unreasonable manner solely because they were private sales.  The Pledgee shall
be under no obligation to delay a sale for the period of time necessary to
permit the issuer of the securities to register such securities for public sale
under the Act, even if the issuer would agree to do so.

     7.  PLEDGOR'S OBLIGATIONS NOT AFFECTED.  The obligations of the Pledgor
under this Agreement shall remain in full force and effect without regard to,
and shall not be impaired or affected by: (a) any amendment or modification of
or addition or supplement to the Loan Agreement, the Term Note or any other
instrument referred to or delivered in connection with the Loan Agreement, or
any assignment or transfer of any thereof; (b) any exercise or non-exercise by
the Pledgee of any right, remedy, power or privilege under or in respect of this
Agreement, the Loan Agreement, the Term Note or any Obligation; (c) any waiver,
consent, extension, indulgence or other action or inaction in respect of this
Agreement, the Loan Agreement, the Term Note or any Obligation; or (d) any
bankruptcy, insolvency, reorganization, arrangement, readjustment, composition,
liquidation, or the like, of the Pledgor and/or the Company; all whether or not
the Pledgor shall have notice or knowledge of any of the foregoing.

     8.  TRANSFER BY THE PLEDGOR; STOCK ISSUANCES.  Without the prior written
consent of the Pledgee, the Pledgor will not sell, assign, transfer or otherwise
dispose of, grant any option with respect to, or mortgage, pledge or otherwise
encumber, any of the Collateral or any interest therein, nor will the Pledgor
permit or suffer to exist any lien or other encumbrance (except in favor of the
Pledgee) on any of the Collateral or any interest therein.  The Pledgor will not
suffer or permit the Company to issue any additional shares of its capital stock
unless same are pledged to the Pledgee as additional Collateral hereunder.

     9.  TERMINATION.  Upon payment in full of the principal of and interest on
the Term Note and performance of all of the Obligations and the expiration or
earlier termination of the term loan arrangements and other credit facilities
provided for by the Loan Agreement, this Agreement shall terminate and such of
the Collateral as has not theretofore been sold or otherwise applied pursuant to
the provisions of this Agreement shall be delivered to the Pledgor.

     10.  NOTICE.  All notices and other communications hereunder shall be in
writing and shall be given in the manner and to the addresses provided for in
the Loan Agreement.

     11.  FURTHER ASSURANCES.  The Pledgor will do all such acts, and will
furnish to the Pledgee all such financing statements, certificates, opinions and
other documents, and will do or cause to be done all such other things, as the
Pledgee may reasonably request from time to time in order to give full effect to
this Agreement and to secure the rights of the Pledgee hereunder.

                                      -4-
<PAGE>

     12.  PLEDGEE'S EXONERATION.  Under no circumstances shall the Pledgee be
deemed to have assumed any responsibility for or obligation or duty with respect
to any part or all of the Collateral beyond the safe custody of any such
Collateral actually delivered to and received by the Pledgee, and the same shall
be at the Pledgor's sole risk at all times except as aforesaid.  The Pledgee
shall not be required to take any action of any kind to collect, preserve or
protect its or the Pledgor's rights in the Collateral or against any other
parties.  The Pledgor hereby releases the Pledgee from any claims, causes of
action and demands at any time arising out of or with respect to this Agreement,
the use of the Collateral and/or any actions taken or omitted to be taken by the
Pledgee acting reasonably and in good faith, and the Pledgor hereby agrees to
hold the Pledgee harmless from and with respect to any and all such claims,
causes of action and demands.  The Pledgee's prior recourse to any part or all
of the Collateral shall not constitute a condition of any demand, suit or
proceeding for payment or collection with respect to any of the Obligations.

     13.  REORGANIZATIONS.  In the event of any one or more reclassifications,
changes, exchanges, stock splits, stock dividends, stock consolidations or other
subdivisions or combinations of the shares of the capital stock of the Company
or any immediate or remote successor to all or substantially all of the business
or assets of the Company pursuant to any one or more of the events described in
this sentence, or consolidations of the Company or any such successor into other
corporations, or other recapitalizations or reorganizations affecting the
Company or any such successor, or any one or more sales or conveyances to
another corporation of the property of the Company or any such successor as an
entirety or substantially as an entirety (each, a "Reorganization"), the Pledgor
will deliver to the Pledgee, in readily transferable form, all securities and
property which come to the Pledgor with respect to the Collateral as a result of
that and any subsequent Reorganization, except for securities and property
surrendered or canceled pursuant to any of same, and such securities and
property shall thereupon become and constitute all or part of the Collateral, as
the case may be.  All sums of money and property paid or distributed in respect
of the Collateral pursuant to a Reorganization which are received by the Pledgor
shall, until paid or delivered to the Pledgee, be held in trust for the Pledgee
to secure the payment of the principal of and interest on the Term Note and the
due performance of and compliance with the Obligations.

     14.  MISCELLANEOUS.  Neither this Agreement nor any provision hereof may be
amended, modified, waived, discharged or terminated orally, but only by an
instrument in writing signed by the party against whom enforcement of the
amendment, modification, waiver, discharge or termination is sought.  The
provisions of this Agreement shall be binding upon and shall inure to the
benefit of the successors and assigns of the Pledgor and the Pledgee.  The
captions in this Agreement are for convenience of reference only and shall not
define or limit the provisions hereof.  This Agreement shall be construed and
enforced in accordance with the laws of The Commonwealth of Massachusetts.  This
Agreement may be executed simultaneously in several counterparts, each of which
will be deemed an original, but all of which together shall constitute one
instrument.  If any term or provision of this Agreement or the application
thereof to any Person, property or circumstance shall to any extent be invalid
or unenforceable, the remainder of this Agreement and the application of such
term or provision to Persons, properties and

                                      -5-
<PAGE>

circumstances other than those as to which it is invalid or unenforceable shall
not be affected thereby, and each term and provision of this Agreement shall be
valid and enforced to the fullest extent permitted by law.

     IN WITNESS WHEREOF, the Pledgor and the Pledgee have caused this Agreement
to be duly executed, as an instrument under seal, as of the day and year first
above written.

                                     PLEDGOR:

                                     CURIS, INC.

                                     By   /s/ George Eldridge
                                       ------------------------------
                                       Name:  George Eldridge
                                       Title: Vice President

                                     PLEDGEE:

                                     FLEET NATIONAL BANK

                                     By   /s/ Kimberly Martone
                                       ------------------------------
                                       Name:  Kimberly Martone
                                       Title: Director

                                      -6-<PAGE>

                                                                   Exhibit 10.25

<TABLE>
<CAPTION>
-----------------------------------------------------------------------------------------------------------------------------------
FORM CD-450   U.S. DEPARTMENT OF COMMERCE
(REV 10/98)
                                                                                             [_]  GRANT    [X] COOPERATIVE
                     FINANCIAL ASSISTANCE AWARD                                              AGREEMENT
                                                                                             --------------------------------------
                                                                                             ACCOUNTING CODE
                                                                                             0/473-1341    Obj. Class: 4110
                                                                                             Req. No. 0/473-3403    $666,666.00
-----------------------------------------------------------------------------------------------------------------------------------
<S>                                                                                          <C>
RECIPIENT NAME                                                                               AWARD NUMBER
Curis, Inc. (Formally Reprogenesis, Inc.)                                                    70NANB0H3010
-----------------------------------------------------------------------------------------------------------------------------------
STREET ADDRESS                                                                               FEDERAL SHARE OF COST
21 Erie Street                                                                               $666,666.00
-----------------------------------------------------------------------------------------------------------------------------------
CITY, STATE, ZIP CODE                                                                        RECIPIENT SHARE OF COST
Cambridge, MA 02139                                                                          $302,511.00
-----------------------------------------------------------------------------------------------------------------------------------
AWARD PERIOD                                                                                 TOTAL ESTIMATED COST
11/01/00-10/31/03 (project period)*                                                          $969,177.00*
-----------------------------------------------------------------------------------------------------------------------------------
AUTHORITY
P.L. 100-418, Section 5131 (Codified at 15 USC 278n) as modified by P.L. 102-245
-----------------------------------------------------------------------------------------------------------------------------------
CFDA NO. 11.612, Advanced Technology Program (ATP), Proposal 00-00-4109
PROJECT TITLE: Biomaterials for Minimally Invasive Therapies
-----------------------------------------------------------------------------------------------------------------------------------
This Award approved by the Grants Officer is issued in triplicate and constitutes an obligation of Federal funding. By signing the
three documents, the Recipient agrees to comply with the Award provisions checked below and attached. Upon acceptance by the
Recipient, two signed Award documents shall be returned to the Grants Officer and the third document shall be retained by the
Recipient. IF not signed and returned without modification by the Recipient within 30 days of receipt, the Grants Officer may
unilaterally terminate this Award.

[X]  Department of Commerce Financial Assistance Standard Terms and Conditions

[X]  Special Award Conditions

[X]  Line Item Budget

[X]  15 CFR Part 14, Uniform Administrative Requirements for Grants and Agreements with Institutions of Higher Education, Hospitals
     Other Non-Profit, and Commercial Organizations

[_]  15 CFR Part, 24, Uniform Administrative Requirements for Grants and agreements to State and Local Governments

[_]  OMB Circular A-21, Cost Principles for Educational Institutions

[_]  OMB Circular A-87, Cost Principles for State, Local, and Indian Tribal Governments

[_]  OMB Circular A-122, Cost Principles for Nonprofit Organizations

[X]  48 CFR Part 31, Contract Cost Principles and Procedures

[_]  OMB Circular A-133, Audits of States, Local Governments, and Non-Profit Organizations

[X]  Other(s) General Terms and Conditions, Advanced Technology Program (ATP)(9/00); Program Specific
              ---------------------------------------------------------------------------------------
              Audit Guidelines for ATP Cooperative Agreements with Single Companies (9/99)
              ----------------------------------------------------------------------------
              * Multi-year Project. See Special Award Condition #6.
              -----------------------------------------------------
              B-AE93-N-C-F-N-A-2-11000  EIN:  52-2239958               473/L. Schilling
-----------------------------------------------------------------------------------------------------------------------------------
SIGNATURE OF DEPARTMENT OF COMMERCE GRANTS OFFICER                                  TITLE                                  DATE
Shamim Shaikh                                                                       Grants Officer                         9/29/00
/s/Shamim Shaikh
-----------------------------------------------------------------------------------------------------------------------------------
TYPED NAME AND SIGNATURE OF AUTHORIZED RECIPIENT OFFICIAL                           TITLE                                  DATE
/s/ Michael P. Gray                                                                 Controller                             10/8/00
-----------------------------------------------------------------------------------------------------------------------------------
</TABLE>
<PAGE>

                           SPECIAL AWARD CONDITIONS
                ADVANCED TECHNOLOGY PROGRAM - SINGLE RECIPIENT
                   Curis, Inc. (Formally Reprogenesis, Inc.)
                    COOPERATIVE AGREEMENT NO. 70NANB0H3010

1.   RECIPIENT ADMINISTRATOR CONTACT

The Recipient Administrator Contact's name, title, address, and telephone number
are:

                         (Technical) Dr. David H. Rine
                                  Curis, Inc.
                                21 Erie Street
                             Cambridge, MA  02139
                            Ph (617) 499-2928 x180
                              Fax (617) 499-2927

                       (Administrative) Michael P. Gray
                            Ph (617) 499-2928 x113
                              Fax (617) 499-2927

2.   GRANTS OFFICER

The Grants Officer's name, address, and telephone number are:

                                 Shamim Shaikh
                 National Institute of Standards and Technology
                    100 Bureau Drive, Bldg. 411, Room 143-A,
                                 Mail Stop 3576
                          Gaithersburg, MD  20899-3576
                                 (301) 975-2367

3.   GRANTS SPECIALIST

The Grant Specialist's name, address, and telephone number are:

                                Dennis Luquette
                National Institute of Standards and Technology
                   100 Bureau Drive, Bldg. 411, Room 143-A,
                                Mail Stop 3576
                         Gaithersburg, MD  20899-3576
                                (301) 975-8002

4.   PROGRAM OFFICERS

a. The Project Manager's name, address, and telephone number are:

                                Linda Schilling
                National Institute of Standards and Technology
                  100 Bureau Drive, Bldg. 101, Mail Stop 4730
                         Gaithersburg, MD  20899-4730
                                (301) 975-2887

b. The Business Specialist's name, address, and telephone number are:

                                  Andy Klein
                National Institute of Standards and Technology
                  100 Bureau Drive, Bldg. 101, Mail Stop 4730
                         Gaithersburg, MD  20899-4730
                                (301) 975-4292

5.   PROJECT DESCRIPTION

All research shall be conducted in accordance with Reprogenesis Inc.'s proposal
dated March 7, 2000, revision dated June 21, 29, 2000, August 1, 4, 8, 9, 2000
and revised budget dated August 8, 2000.

6.  funding limitations

The scope of work and budget incorporated into this award cover a three-year
                                                                  ----------
period (referred to as the "project period") for a total amount of $2,000,000.00
in Federal funds.  However, Federal funding available at this time is limited to
$666,666.00 for the first year period from 11/01/00 through 10/31/01 (referred
                                           -------------------------
to as the "budget period"). The Grants Officer may require additional
clarification to support the budget. If that results in changes to the budget
or budget narrative, the Recipient shall submit, in writing, a revised budget
and/or budget narrative to the Grants Officer for approval.  Receipt of any
funding beyond the first year up to the level projected under this award is
contingent upon the availability of funds from Congress, satisfactory
performance, and will be at the sole discretion of the National Institute of
Standards and Technology (NIST). The Recipient may not obligate, incur any
expenditure, nor engage in any commitments which involve any amount in excess of
the Federal amount presently available. No legal liability exists or will
result on the part of the Federal Government for payment of any portion of the
remaining funds, which have not been made available under the award.  If
additional funds are not made available, any expenses incurred related to
closeout activities must be funded from the amount already made available under
this award.  The notice of availability or non-availability of additional
funding for the second and third years will be made in writing by the Grants
                                                               -------------
Officer. Only the Grants Officer is authorized to obligate funds. No other
-------
verbal
<PAGE>

or written notice should be relied upon by the Recipient. In the absence of a
written notice of additional funding, no assumption should be made by the
Recipient that the funds will be forth coming, and no costs should be incurred
in excess of funding already provided.

Projected budget amounts and periods:

Year 2: $ 666,667 (From 11/01/01 to 10/31/02)

Year 3: $ 666,667 (From 11/01/02 to 10/31/03)

7.   COST SHARE

For the first year period, the cost sharing ratio (direct cost only) applicable
to this award is the Recipient's contribution of 31.22% ($302,511.00) and NIST's
contribution of 68.78% ($666,666.00).

8.   RESTRICTION ON USE OF VERTEBRATE ANIMALS

Based upon materials submitted by the Recipient and reviewed by the appropriate
NIST officials, NIST has determined that the proposed research complies, as
applicable, with the Animal Welfare Act as amended, (7 USC 2131 et seq.,
implementing regulations 9 CFR parts 1, 2, and 3), and other Federal statutes
and regulations relating to vertebrate animals.  Therefore, the proposed
research involving vertebrate animals is approved for

Facility 1: Brown University (Sheep)

Facility 2: The Center for Blood Research (Mouse/Rat)

Which are the only facilities authorized to conduct research involving
vertebrate animals under this award.

In order to continue research involving vertebrate animals, the Recipient must
maintain the following valid, current approvals, and certifications.

Facility 1: Brown University

Protocol # 53-00, Titles: Host response to injection of autologous Chondrocyte
hydrogel suspension injected into sheep bladder.
Species: Sheep
Expiration date 5/26/01

Animal Welfare Assurance # A 3284-01 Expiration date not given.

USDA # 15-R-0003 Expiration date 10/27/02

Facility 2: The Center for Blood Research

Protocol # 14M1199 Titles: Tissue formation in cell-containing hydrogels
Species: Mouse/Rat
Expiration date 12/21/02

Animal Welfare Assurance # A 3251 Expiration date not given.

The Recipient shall provide documentation in evidence of the renewal of all
approvals and certifications upon receipt from the IACUC and/or the cognizant
certifying body, but in any case, no later than the expiration date shown above.
The Recipient shall provide to the NIST Grants Officer documentation of
continuing review of the ASP as it occurs.

The Recipient shall immediately inform the ATP Project Manager and NIST Grants
Officer in writing of any proposed deviation from the procedures involving
vertebrate animals approved by NIST during the project period, and submit
documentation evidencing approval of the revised animal study proposal by the
IACUC for NIST review.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00023-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00023-of-00352.parquet"}]]